{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:15:47Z","timestamp":1791281747607,"version":"4.1.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JRS"],"published-print":{"date-parts":[[2023,1,13]]},"abstract":"<jats:p>BACKGROUND: Gender dysphoria is characterised by a sense of distress because of discordance between the self-perception of gender identity and the assigned sex. Hormonal treatment of transgender males uses testosterone to induce and preserve masculinisation. OBJECTIVE: The study investigated the safety of testosterone therapy in transgender males. METHODS: The present study used a retrospective file review of transgender male subjects who were treated with testosterone (initially transdermal testosterone gel and subsequently parenteral testosterone undecanoate) for at least 18 months and had subsequently achieved a serum testosterone level within the normal range of cisgender male counterparts. Changes in somatometric data and blood biomarkers were investigated. RESULTS: The mean testosterone serum levels after approximately 18 months of treatment were about 545 ng\/dL (SD \u00b1 94 ng\/dL). There was a statistically significant rise in body mass index (\ud835\udf12d = +1.23 kg\/m2) with a reduction in blood glucose (\ud835\udf12d = \u22125.33 mg\/dL) as well as statistically significant increases in aspartate transaminase (\ud835\udf12d = +4.3 U\/L), haemoglobin (\ud835\udf12d = +1.72 g\/dL), and haematocrit (\ud835\udf12d = +4.76%). In contrast, there were no significant changes in the lipidaemic profile of the subjects. CONCLUSIONS: Treatment with testosterone is routinely used for the promotion of virilising physical changes in transgender males. However, the likelihood of adverse effects of continuous treatment is still unclear. This study contributed to the notion that achieving testosterone levels within the target range is a prerequisite for the safety of the gender-affirming treatment.<\/jats:p>","DOI":"10.3233\/jrs-200087","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T11:02:14Z","timestamp":1660302134000},"page":"21-28","source":"Crossref","is-referenced-by-count":7,"title":["The metabolic effects of hormonal treatment in transgender males: Safety of the testosterone gender-affirming therapy"],"prefix":"10.1177","volume":"34","author":[{"given":"Charalampos","family":"Milionis","sequence":"first","affiliation":[{"name":", , , , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Ilias","sequence":"additional","affiliation":[{"name":", , , , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaggelia","family":"Venaki","sequence":"additional","affiliation":[{"name":", , , , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eftychia","family":"Koukkou","sequence":"additional","affiliation":[{"name":", , , , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"9","key":"10.3233\/JRS-200087_ref1","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nrendo.2014.108","article-title":"Management of disorders of sex development","volume":"10","author":"Hiort","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"20","key":"10.3233\/JRS-200087_ref2","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1007\/s00018-008-8109-z","article-title":"Sex determination in mammals \u2013 before and after the evolution of SRY","volume":"65","author":"Wallis","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"1\u20133","key":"10.3233\/JRS-200087_ref3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000339511","article-title":"Genetic control of ovarian development","volume":"7","author":"Tevosian","year":"2013","journal-title":"Sex Dev"},{"issue":"1","key":"10.3233\/JRS-200087_ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4111\/kju.2012.53.1.1","article-title":"Disorders of sex development","volume":"53","author":"Kim","year":"2012","journal-title":"Korean J Urol"},{"key":"10.3233\/JRS-200087_ref5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-clinpsy-021815-093034","article-title":"Gender dysphoria in adults","volume":"12","author":"Zucker","year":"2016","journal-title":"Annu Rev Clin Psychol"},{"issue":"6","key":"10.3233\/JRS-200087_ref6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2105\/AJPH.2007.127811","article-title":"Sexual and gender minority health: What we know and what needs to be done","volume":"98","author":"Mayer","year":"2008","journal-title":"Am J Public Health"},{"issue":"5","key":"10.3233\/JRS-200087_ref7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1071\/SH17067","article-title":"Epidemiology of gender dysphoria and transgender identity","volume":"14","author":"Zucker","year":"2017","journal-title":"Sex Health"},{"issue":"4","key":"10.3233\/JRS-200087_ref8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jsxm.2016.02.001","article-title":"Prevalence of transgender depends on the \u201ccase\u201d definition: A systematic review","volume":"13","author":"Collin","year":"2016","journal-title":"J Sex Med"},{"issue":"4","key":"10.3233\/JRS-200087_ref9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jsxm.2020.01.012","article-title":"European Society for Sexual Medicine position statement \u201cAssessment and hormonal management in adolescent and adult trans people, with attention for sexual function and satisfaction\u201d","volume":"17","author":"T\u2019Sjoen","year":"2020","journal-title":"J Sex Med"},{"issue":"6","key":"10.3233\/JRS-200087_ref10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.21037\/tau.2016.09.04","article-title":"Hormone therapy for transgender patients","volume":"5","author":"Unger","year":"2016","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.3233\/JRS-200087_ref11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2265.2004.02174.x","article-title":"Normal, bound and nonbound testosterone levels in normally ageing men: Results from the Massachusetts Male Ageing Study","volume":"62","author":"Mohr","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"43","key":"10.3233\/JRS-200087_ref12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3238\/arztebl.2020.0725","article-title":"Hormonal gender reassignment treatment for gender dysphoria","volume":"117","author":"Meyer","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"11","key":"10.3233\/JRS-200087_ref13","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: An Endocrine Society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.3233\/JRS-200087_ref14","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.3233\/JRS-200087_ref15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/2042098614548680","article-title":"Adverse effects of testosterone replacement therapy: An update on the evidence and controversy","volume":"5","author":"Grech","year":"2014","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"10.3233\/JRS-200087_ref16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jcte.2015.02.003","article-title":"Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals","volume":"2","author":"Weinand","year":"2015","journal-title":"J Clin Transl Endocrinol"},{"key":"10.3233\/JRS-200087_ref17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/DMSO.S50777","article-title":"Testosterone levels and type 2 diabetes in men: Current knowledge and clinical implications","volume":"7","author":"Beatrice","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"10.3233\/JRS-200087_ref18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/XCE.0000000000000061","article-title":"Effects of testosterone replacement on glucose and lipid metabolism","volume":"4","author":"Errazuriz","year":"2015","journal-title":"Cardiovasc Endocrinol"},{"issue":"1","key":"10.3233\/JRS-200087_ref19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1210\/jcem.79.1.8027240","article-title":"Induction of insulin resistance by androgens and estrogens","volume":"79","author":"Polderman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.3233\/JRS-200087_ref20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1046\/j.1365-2265.2003.01753.x","article-title":"Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects","volume":"58","author":"Elbers","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.3233\/JRS-200087_ref21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/andr.12382","article-title":"Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: A systematic review","volume":"5","author":"Velho","year":"2017","journal-title":"Andrology"},{"issue":"2","key":"10.3233\/JRS-200087_ref22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1530\/EJE-14-0586","article-title":"Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI)","volume":"172","author":"Van Caenegem","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.3233\/JRS-200087_ref23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1210\/er.2018-00011","article-title":"Endocrinology of transgender medicine","volume":"40","author":"T\u2019Sjoen","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"10.3233\/JRS-200087_ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2265.2009.03632.x","article-title":"Effect of sex steroid use on cardiovascular risk in transsexual individuals: A systematic review and meta-analyses","volume":"72","author":"Elamin","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.3233\/JRS-200087_ref25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11154-018-9454-3","article-title":"Cardiovascular health in transgender people","volume":"19","author":"Irwig","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"10.3233\/JRS-200087_ref26","doi-asserted-by":"publisher","first-page":"183041","DOI":"10.1155\/2013\/183041","article-title":"Testosterone-induced effects on lipids and inflammation","volume":"2013","author":"Vodo","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.3233\/JRS-200087_ref27","doi-asserted-by":"publisher","DOI":"10.1177\/2048004019880745","article-title":"Cardiovascular disease in transgendered people: A review of the literature and discussion of risk","volume":"8","author":"Seal","year":"2019","journal-title":"JRSM Cardiovasc Dis"},{"issue":"5","key":"10.3233\/JRS-200087_ref28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0038-1657788","article-title":"Recommendations for the use of testosterone in male transgender","volume":"40","author":"Costa","year":"2018","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"1","key":"10.3233\/JRS-200087_ref29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0970-1591.124197","article-title":"Risks of testosterone replacement therapy in men","volume":"30","author":"Osterberg","year":"2014","journal-title":"Indian J Urol"},{"issue":"6","key":"10.3233\/JRS-200087_ref30","first-page":"1105","article-title":"Mildly elevated liver transaminase levels in the asymptomatic patient","volume":"71","author":"Giboney","year":"2005","journal-title":"Am Fam Physician"},{"issue":"3","key":"10.3233\/JRS-200087_ref31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/andr.12485","article-title":"Prospective evaluation of hematocrit in gender-affirming hormone treatment: Results from European network for the investigation of gender incongruence","volume":"6","author":"Defreyne","year":"2018","journal-title":"Andrology"},{"issue":"2","key":"10.3233\/JRS-200087_ref32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ajh.24593","article-title":"Thrombotic issues in transgender medicine: A review","volume":"92","author":"Shatzel","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.3233\/JRS-200087_ref33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.sxmr.2017.04.001","article-title":"Erythrocytosis following testosterone therapy","volume":"6","author":"Ohlander","year":"2018","journal-title":"Sex Med Rev"},{"issue":"2","key":"10.3233\/JRS-200087_ref34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2013.12.003","article-title":"The sex difference in haemoglobin levels in adults \u2013 mechanisms, causes, and consequences","volume":"28","author":"Murphy","year":"2014","journal-title":"Blood Rev"},{"key":"10.3233\/JRS-200087_ref35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cca.2019.02.011","article-title":"Hematology reference intervals for transgender adults on stable hormone therapy","volume":"492","author":"Greene","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.3233\/JRS-200087_ref36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1210\/jc.2007-1809","article-title":"Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience","volume":"93","author":"Gooren","year":"2008","journal-title":"J Clin Endocrinol Metab"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JRS-200087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:32Z","timestamp":1777509932000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JRS-200087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":36,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jrs-200087","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}